Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ovid Therapeutics Inc.OVID · Entity 5411 | Director · President and CEO | February 23, 2026 | March 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ovid Therapeutics Inc.
Report date February 23, 2026 · Filed March 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 61,750 |
Reported balance
After 2026-02-23 transaction · row 1
1 source rowRow 1 · 2026-02-23 · Sale · Disposed 11,656 · Balance 61,750 F1: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.45 to $1.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.65 · Expires 2036-02-25 | Direct | 1,435,000 |
Reported balance
After 2026-02-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-26 · Grant · Acquired 1,435,000 · Balance 1,435,000 F3: The shares subject to the stock option will vest in 48 equal monthly installments commencing on March 20, 2026, subject to the Reporting Person's continued services through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
F2: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.45 to $1.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The shares subject to the stock option will vest in 48 equal monthly installments commencing on March 20, 2026, subject to the Reporting Person's continued services through each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2026 Filed Mar 2, 2026 16:30 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantEmployee Stock Option (Right to Buy) · Derivative | 1,435,000 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0002036798-26-000004 · form4-03022026_040303.xml · derivative · entry 2 ALEXANDER MARGARET A. · CIK 0002036798 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,435,000 Underlying: Common Stock · 1,435,000 shares Expires 2036-02-25 F3 · derivative.exercise_date: The shares subject to the stock option will vest in 48 equal monthly installments commencing on March 20, 2026, subject to the Reporting Person's continued services through each such date. Read SEC document |
| February 23, 2026 Filed Mar 2, 2026 16:30 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | SaleCommon Stock | 11,656 | $1.45 | $16,901.20 |
DisclosureSEC source: 0002036798-26-000004 · form4-03022026_040303.xml · nonDerivative · entry 1 ALEXANDER MARGARET A. · CIK 0002036798 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,750 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.45 to $1.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 04, 2026 Filed Jan 5, 2026 17:55 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantEmployee Stock Option (right to buy) · Derivative | 890,000 | $0.00 Strike: $1.76 | $0.00 |
DisclosureSEC source: 0002036798-26-000002 · form4-01052026_050101.xml · derivative · entry 1 ALEXANDER MARGARET A. · CIK 0002036798 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 890,000 Underlying: Common Stock · 890,000 shares Expires 2036-01-03 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on January 1, 2027 and the remaining shares will vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued services through such date. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 16:15 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | SaleCommon Stock | 5,279 | $0.56 | $2,956.24 |
DisclosureSEC source: 0001415889-25-005998 · form4-02282025_040204.xml · nonDerivative · entry 1 ALEXANDER MARGARET A. · CIK 0002036798 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,406 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. Read SEC document |
| February 20, 2025 Filed Feb 24, 2025 19:55 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantEmployee Stock Option (Right to Buy) · Derivative | 262,500 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001415889-25-005366 · form4-02242025_070201.xml · derivative · entry 2 ALEXANDER MARGARET A. · CIK 0002036798 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 262,500 Underlying: Common Stock · 262,500 shares Expires 2035-02-19 F3 · derivative.exercise_date: The shares subject to the stock option will vest in 48 equal monthly installments commencing on March 20, 2025, subject to the Reporting Person's continued services through each such date. Read SEC document |
| February 20, 2025 Filed Feb 24, 2025 19:55 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantCommon Stock | 43,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-005366 · form4-02242025_070201.xml · nonDerivative · entry 1 ALEXANDER MARGARET A. · CIK 0002036798 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,685 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs will vest in three equal annual installments commencing on February 22, 2026, subject to the Reporting Person's continuous service through each such vesting date. F2 · price: Each RSU represents a contingent right to receive one share of Common Stock. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 09:18 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | PurchaseCommon Stock | 6,810 | $0.73 | $4,971.30 |
DisclosureSEC source: 0001415889-25-002230 · form4-01292025_020104.xml · nonDerivative · entry 1 ALEXANDER MARGARET A. · CIK 0002036798 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,935 Read SEC document |
| September 09, 2024 Filed Sep 11, 2024 17:38 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantEmployee Stock Option (right to buy) · Derivative | 140,000 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0001415889-24-023237 · form4-09112024_090958.xml · derivative · entry 1 ALEXANDER MARGARET A. · CIK 0002036798 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2034-09-08 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on September 9, 2025 and the remaining shares will vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued services through such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.